Features | Partner Sites | Information | LinkXpress
Sign In
JIB
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING

Ingenuity Systems Acquired by Qiagen, Adding Analysis, Interpretation of Complex Biologic Data Technology

By BiotechDaily International staff writers
Posted on 07 May 2013
Qiagen NV (Hilden, Germany) has acquired Ingenuity Systems, Inc. (Redwood City, CA, USA), a leading provider of biomedical software that effectively analyzes and interprets the biologic meaning of genomic data. Ingenuity has created a curated knowledge system of biomedical data and analysis solutions for the investigation, interpretation, and analysis of complex biologic systems.

New developments such as next-generation sequencing (NGS) are now generating more data in only one year than was generated in all prior history, making the analysis and interpretation of this wide-ranging and very complex biologic data a critical success factor.

At the core of Ingenuity’s product range is the Ingenuity Knowledge Base, a 14-year endeavor to effectively and manually curate, model, and computationally structure the immense amount of biomedical literature, including genomic variations associated with human disease and thousands of disease models. The Ingenuity Knowledge Base and software applications enable users to accurately interpret the significance of increasingly large amounts of biologic data to better direct research and medical treatment decisions.

Ingenuity’s Knowledge Base is constructed on algorithms that pair all human gene variants with biologic interpretations based on known outcomes and discoveries. These pairings are gathered and reviewed by specialists (curated) in a standardized way from a wide range of sources including clinical and scientific publications with the support of advanced technology and refined processes. This process and the associated learning algorithms translate sourced data into interoperable and linkable collections of relevant information.

The Ingenuity product range includes the Ingenuity pathways analysis (IPA) standard web-based software application, which enables researchers to model, analyze, and determine the complex biologic systems at the core of life sciences research. IPA is deployed in most major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports data analysis and interpretation from all high-throughput analysis platforms and it is used in virtually all areas of drug discovery and development from target identification and validation to predictive toxicology, biomarkers, and pharmacogenomics.

Ingenuity variant analysis is a web-based NGS data analysis application that solves a vital requirement for researchers trying to rapidly identify relevant causal variants in human diseases in a matter of hours. It enables customers to rapidly identify and prioritize variants by drilling down to a small, targeted subset of compelling variants based upon published biologic evidence and their own knowledge of disease biology. Users can also probe variants from multiple biologic standpoints, examine different biologic theories, and identify the most promising variants for follow-up analysis.

Up to now, thousands of users from leading institutions around the world have already uploaded genomic data using Ingenuity variant analysis, which has been used to analyze more than 45,000 biologic samples. In February 2013, Ingenuity had passed an audit under the US Health Insurance Portability and Accountability Act (HIPAA) and complies with the US-EU Safe Harbor framework.

Ingenuity will substantially expand and strengthen Qiagen’s own curated database, which is embedded in wet lab assays and marketed through Qiagen’s GeneGlobe content portal. GeneGlobe offers hundreds of assay panels for polymerase chain reaction (PCR) and NGS as well as more than 60,000 fully annotated molecular assays for the most sought-after diseases and pathways, curated from the biomedical literature.

Related Links:
Qiagen



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Diagram illustrates the innovative process that could lead to more effective drugs against influenza infection (Photo courtesy of the Hebrew University of Jerusalem).

Researchers Show How the Influenza Virus Blocks Natural Killer Cell Recognition

A team of molecular virologists has described how the influenza virus evolved a defense mechanism to protect it from attack by the immune system's natural killer (NK) cells. The recognition of pathogen-infected... Read more

Drug Discovery

view channel
Image: Synthetic ion transporters can induce apoptosis by facilitating chloride anion transport into cells (Photo courtesy of the University of Texas, Austin).

Experimental Drug Kills Cancer Cells by Interfering with Their Ion Transport Mechanism

An experimental anticancer drug induces cells to enter a molecular pathway leading to apoptosis by skewing their ion transport systems to greatly favor the influx of chloride anions. To promote development... Read more

Therapeutics

view channel
Image: Liver cells regenerated in mice treated with a new drug (right) compared with a control group (center) after partial liver removal. Healthy liver cells are shown at left (Photo courtesy of Marshall et al, 2014, the Journal of Experimental Medicine).

New Drug Triggers Liver Regeneration After Surgery

Investigators have revealed that an innovative complement inhibitor decreases complement-mediated liver cell death, and actually stimulates postsurgery liver regrowth in mice. Liver cancer often results... Read more

Lab Technologies

view channel

Genome-Wide Mutation-Searching Computational Software Designed for Genomic Medicine

Analysis software cross-references a patient’s symptoms with his genome sequence to help physicians in the diagnosis of disease. This software was created by a team of scientists from A*STAR’s Genome Institute of Singapore (GIS), led by Dr. Pauline Ng. The research findings were published August 3, 2014, in the journal... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.